Widespread distribution of gene products at clinically relevant levels throughout the CNS
has been challenging. Adeno-associated virus type 9 (AAV9) vector has been reported as a …

Delivery of adeno-associated viral (AAV) vectors into the cerebrospinal fluid (CSF) can
achieve gene transfer to cells throughout the brain and spinal cord, potentially making many …

We used convection-enhanced delivery (CED) to characterize gene delivery mediated by
adeno-associated virus type 1 (AAV1) by tracking expression of hrGFP (humanized green …

Background Adeno-associated virus (AAV) vectors are a promising vehicle for noninvasive
gene delivery to the central nervous system via intravenous infusion. However, naturally …

Vectors derived from adeno-associated virus (AAV) are promising candidates for neural cell
transduction in vivo because they are nonpathogenic and achieve long-term transduction in …

Adeno-associated viral vectors (AAVs) have demonstrated potential in applications for
neurologic disorders, and the discovery that some AAVs can cross the blood-brain barrier …

Adeno-associated virus (AAV) vectors have gained a preeminent position in the field of gene
delivery to the normal brain through their ability to achieve extensive transduction of neurons …

Epidemiological studies report that 80% of the population maintains antibodies (Ab) to wild-
type (wt) adeno-associated virus type 2 (AAV2), with 30% expressing neutralizing Ab (NAb) …

Recombinant adeno-associated virus 2 (rAAV2) has been shown to deliver genes to
neurons effectively in the brain, retina, and spinal cord. The characterization of new AAV …

A wide diversity of adeno-associated virus (AAV) structural proteins uncovered from latent
genomes in primate tissue has expanded the number of AAV vector serotypes, which can …